ICH Q14: ANALYTICAL PROCEDURE DEVELOPMENT (HARMONISED GUIDELINE)

Summary

ICH Q14 is a harmonized guideline providing a comprehensive, science- and risk-based framework for developing analytical procedures. It is designed to work in parallel with the revised ICH Q2(R2) on method validation and encourages a systematic approach that can yield more robust, reliable methods and greater post-approval flexibility.

The guideline introduces two pathways for analytical development:

  • Minimal (Traditional) Approach – the historical empirical development route.

  • Enhanced Approach – a structured, Quality by Design (QbD) methodology that fosters deep understanding of method performance and sources of variability.

Key Principles & Scope

ICH Q14 provides guidance for developing analytical procedures for testing drug substances and products (chemical and biological), including for release and stability. Primarily applies to drug substances and products for release/stability; excipients, in-process tests, and non-GMP testing are out of scope.

Core Principle: To promote robust, fit-for-purpose analytical methods through deep scientific understanding. This ensures consistent performance and simplifies post-approval changes.

Key Concepts:

  • Minimal (Traditional) Approach: Empirical development where post-approval changes typically require regulatory approval.
  • Enhanced Approach: A systematic, science-based approach using Quality by Design (QbD) principles, which can offer greater regulatory flexibility. It involves:
    • Analytical Target Profile (ATP): A prospective statement defining the intended purpose and the method’s performance requirements.
    • Risk Assessment: Identifies Critical Method Parameters (CMPs) that affect performance.
    • Systematic Development (e.g., DoE): Studies CMPs to understand their impact.
    • Method Operational Design Region (MODR): An optional, justified range for critical parameters, which if accepted by regulators, allows flexibility for post-approval adjustments without resubmission
  • Both pathways are acceptable; sponsors may choose based on product and development context

Official Source

https://www.ema.europa.eu/en/ich-q14-analytical-procedure-development-scientific-guideline

Supporting Materials

These related links show posts on this site that reference this page. They do not necessarily mean that this guidance directly applies to every modality, product type, or quality attribute listed below.

Related Quality Attribute Posts